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Minnesota, Minneapolis, MN, United StatesBackground & Aims: Lysosomal acid lipase deﬁciency is an auto-
somal recessive enzyme deﬁciency resulting in lysosomal accu-
mulation of cholesteryl esters and triglycerides. LAL-CL04, an
ongoing extension study, investigates the long-term effects of
sebelipase alfa, a recombinant human lysosomal acid lipase.
Methods: Sebelipase alfa (1 mg/kg or 3 mg/kg) was infused
every-other-week to eligible subjects. Safety and tolerability
assessments, including liver function, lipid proﬁles and liver vol-
ume assessment, were carried out at regular intervals.
Results: 216 infusions were administered to eight adult subjects
through week 52 during LAL-CL04. At week 52, mean alanine
aminotransferase and aspartate aminotransferase levels were
normal with mean change from baseline of 58% and 40%.
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related reaction; MN, multiples of normal.triglyceride and high-density lipoprotein were 60%, 39%,
36%, and +29%, respectively. Mean liver volume by magnetic
resonance imaging and hepatic proton density fat fraction
decreased (12% and 55%, respectively). Adverse events were
mainly mild and unrelated to sebelipase alfa. Infusion-related
reactions were uncommon: three events of moderate severity
were reported in two subjects; one patient’s event was suggestive
of a hypersensitivity-like reaction, but additional testing did
not conﬁrm this, and the subject has successfully re-started
sebelipase alfa. Of samples tested to date, no anti-drug antibodies
have been detected.
Conclusions: Long-term dosing with sebelipase alfa in lysosomal
acid lipase-deﬁcient patients is well tolerated and produces sus-
tained reductions in transaminases, improvements in serum lipid
proﬁle and reduction in the hepatic fat fraction. A randomized,
placebo-controlled phase 3 trial in children and adults is under-
way (ARISE: NCT01757184).
 2014 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
Lysosomal Acid Lipase (LAL) Deﬁciency (LAL D) (OMIMD 278000)
is an autosomal recessive disease that is associated with signiﬁ-
cant morbidity and shortened life expectancy. Mutations in the
LIPA gene markedly decrease LAL enzyme activity leading to14 vol. 61 j 1135–1142
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lysosomal cholesteryl ester (CE) and triglyceride (TG) accumula-
tion. Although the LIPA gene is expressed in many tissues, lyso-
somal accumulation of undigested lipids is prominent in cells
of the monocyte/macrophage lineage, in the liver and hepato-
cytes [1]. Common clinical manifestations include serum trans-
aminase elevation, hepatomegaly, hepatic lipid accumulation,
and dyslipidemia. This presentation, historically known as cho-
lesteryl ester storage disease, is an underappreciated cause of
liver ﬁbrosis with frequent progression to cirrhosis [2]. LAL D is
also associated with evidence of premature atherosclerosis in
some cases [3–10]. Clinical diagnosis is challenging due to the
prevalence (1:40,000 to 1:300,000 [3,11]) and manifestations
that overlap with more common liver/lipid disorders.
In contrast to non-alcoholic fatty liver disease (NAFLD) and
non-alcoholic steatohepatitis (NASH), where the pathogenesis is
not fully understood, LAL D leads to CE and TG accumulation in
hepatocytes and liver macrophages with progression to ﬁbrosis.
The high frequency of liver ﬁbrosis with cirrhosis development
in LAL D, for some as early as 6 months of age, suggests that
the accumulation of lysosomal CE and TG is a potent driver of
liver ﬁbrosis [2,12–14]. In the rat disease model of LAL D, liver
ﬁbrosis also develops rapidly (within 4–8 weeks) in association
with abnormal lipid accumulation. Concordant reduction in liver
CE, TG, alpha smooth muscle actin staining and ﬁbrosis with
sebelipase alfa (a recombinant human LAL enzyme; Synageva
BioPharma Corp., Lexington, MA, US) highlights the importance
of lysosomal CE and TG accumulation as a driver of ﬁbrosis [15].
Current medical management of LAL D is limited and includes
the use of HMG-CoA reductase inhibitors (statins) alone or in
combination with other lipid-lowering therapies for disease-
associated hypercholesterolemia. Although these agents can
reduce serum cholesterol and TG concentrations, these changes
are not accompanied by consistent improvements in serum
transaminases or substantial reductions in hepatic CE or TG con-
tent [2,16]. These ﬁndings, and the observed decreases in stellate
cell activation and ﬁbrosis concordant with hepatic lipid reduc-
tion in the rat model, point to the importance of hepatic lipid
reduction in the amelioration of liver disease progression in these
patients.
The initial effects of sebelipase alfa in LAL D adults in the
LAL-CL01 study and effects up to 12 weeks in the LAL-CL04 study
have been reported [17]. We now provide evidence of these
beneﬁcial effects on biochemical markers of disease activity up
to week 52, describe for the ﬁrst time improvements in hepatic
lipid content, and additionally report longer term safety.Patients and methods
Study design
LAL-CL04 (trial registration number: NCT01488097) is an ongoing open-label,
multicentre, extension study of LAL-CL01 (NCT01307098) involving eight sites
in ﬁve countries. Subjects who completed the LAL-CL01 study were eligible to
enrol in this extension study (Fig. 1).
The dose schedule in the LAL-CL04 study consisted of four once-weekly infu-
sions of sebelipase alfa at the same dose as in the LAL-CL01 study (0.35, 1.0 or
3.0 mg/kg) followed by every-other-week infusions of sebelipase alfa (1.0 or
3.0 mg/kg).
The study protocol conforms to the ethical guidelines of the 1975 Declaration
of Helsinki and Good Clinical practice guidelines. Ethics committees and/or insti-
tutional review boards at participating institutions reviewed and approved the
protocol. All subjects provided informed written consent before undergoing
study-speciﬁc assessments or procedures.1136 Journal of Hepatology 2014Investigations
The objectives of LAL-CL04 were to evaluate the long-term safety, pharmacoki-
netics, pharmacodynamics, and immunogenicity of sebelipase alfa. Pharmacody-
namic and clinical effects were assessed by measuring alanine aminotransferase
(ALT), aspartate aminotransferase (AST), total cholesterol, TGs, low-density lipo-
protein (LDL), high-density lipoprotein (HDL), alkaline phosphatase, gamma-glut-
amyl transferase (GGT), C-reactive protein and ferritin. Liver volume was assessed
by MRI and the hepatic proton density fat fraction (PDFF), a measure of lipid
content, was assessed by MRI (multi-echo gradient-echo sequence imaging) or
1H-MRS (if available) [18–21].
Safety assessments included treatment-related adverse events (AEs), vital
signs, physical examination, electrocardiography, and routine laboratory tests
at regular intervals. AEs were graded using the National Cancer Institute Common
Terminology Criteria for adverse events (CTCAE), version 4.0 or higher. Infusion-
related reactions (IRRs) were deﬁned as any AE that occurred during the 2-h infu-
sion or within 4 h after the infusion and assessed by the investigator as at least
possibly related to the study drug.
Anti-drug antibody assays
The presence of serum anti-sebelipase alfa antibodies was examined by use of a
validated bridging enzyme-linked immunosorbent assay [22,23]. Additional
methodological details have been published previously [17].
Statistical analysis
Subjects who received at least one dose of sebelipase alfa in LAL-CL04 were ana-
lysed for safety; AEs, vital signs, and laboratory tests were summarized. Statistical
comparisons of the dosing cohorts were not performed, as the study was not
powered to detect differences between them. Data from the two cohorts were
pooled and descriptive statistics were used to compare to baseline parameters
from LAL-CL01. Changes and percent changes from baseline in serum transami-
nases, serum lipids, acute phase reactants, hepatic PDFF and liver volumes were
summarized with no speciﬁc statistical hypothesis testing. Exploratory statistical
analyses were performed to examine the effects of sebelipase alfa on key activity
parameters. The Wilcoxon sign-rank test was used for statistical tests of change
from baseline, without adjustment for multiplicity. For each measure, only the
p value for the absolute change from baseline was calculated; this p value was
used to describe the change from baseline regardless of the summary statistic
that is displayed (i.e., change from baseline or percentage change from baseline).
Starting with the week 4 visit, laboratory assessments were performed two
weeks post-infusion. In order to further investigate the post-infusion increases
in LDL and TG an additional serum biochemistry assessment was scheduled
one week post-infusion (between week 24 and 28). In the graphs, all 1-week-
post-infusion laboratory data are presented one week after the week 24 visit.
For end points calculated as change from baseline, the LAL-CL01 study baseline
was used, with the exception of the liver volume and hepatic PDFF end points,
which were ﬁrst performed using MRI/MRS at baseline of LAL-CL04. Liver volume
is displayed as multiples of normal (MN, where ‘‘normal’’ liver volume in litres
was deﬁned as 2.5% of body weight in kg). Hepatic PDFF is reported for the right
lobe of the liver using either MRI (n = 4 subjects) or MRS (n = 2 subjects). Percent-
age change from baseline was computed for all six subjects and combined to form
the mean percentage change in hepatic PDFF.Results
The ﬁrst subject entered LAL-CL04 on 12 December 2011; the last
subject completed the last visit on 15 May 2013. Of the nine sub-
jects who completed LAL-CL01, eight enrolled in LAL-CL04 with a
median of 18 weeks (range 9 to 28 weeks) between the last dose
of sebelipase alfa in LAL-CL01 and the ﬁrst dose in LAL-CL04. One
subject (#4) did not enrol in LAL-CL04. The subject completed
LAL-CL01, but was subsequently lost to follow-up. When the
patient made contact with the trial centre again approximately
9 months after completing LAL-CL01, the patient had already
developed liver failure, manifested by oedema, fatigue and grade
1 hepatic encephalopathy. The patient was no longer eligible forvol. 61 j 1135–1142
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Fig. 1. Flow chart diagram of the LAL-CL01 and LAL-CL04 study design. Subjects (18–65 yr) were required to have documented LAL deﬁciency, hepatomegaly and/or
transaminases >1.5  ULN, and may be on a lipid-lowering agents (stable dose for P4 weeks). LAL, Lysosomal acid lipase; qw, once weekly; qow, once every other week.
Table 1. Baseline demographic and disease characteristics of all subjects in LAL-CL04.
Subject 1 2* 3 5 6 7 8 9 Mean ± SD
LAL-CL01 dose (mg/kg) 0.35 0.35 0.35 1 1 3 3 3 -
LAL-CL04 dose (Wk 1 to 4) (mg/kg) 0.35 0.35 0.35 1 1 3 3 3 -
LAL-CL04 dose (Wk 6 to 52) (mg/kg) 1 1 1 1 1 3 3 3 -
Demographics
Baseline age (yr) 41 29 27 45 19 21 19 41 30 ± 11
Gender M M F M M M F M 75% M
Baseline BMI 27.8 22.6 20.5 25.1 23.5 25.2 26.6 27.4 24.8 ± 2.5
Baseline laboratory assessments
ALT (U/L) 60 76↑ 85↑ 70↑ 119↑ 86↑ 57 110↑ 83 ± 22
AST (U/L) 56↑ 48 69↑ 52↑ 69↑ 41 37 65↑ 53 ± 12
GGT (U/L) 40 34 12 42 26 55 23 203↑ 54 ± 61
Total cholesterol (mg/dl) 130 391↑ 256↑ 116 178 188 182 220 169 ± 39
HDL-cholesterol (mg/dl) 28↓ 41 39 22↓ 45 43 49 26↓ 40 ± 9
LDL-cholesterol (mg/dl) 74 300↑ 208↑ 70 118 112 135 143 145 ± 76
Triglycerides (mg/dl) 218↑ 108 106 102 92 266↑ 80 277↑ 147 ± 85
ALP (U/L) 93 97 76 86 135↑ 100 76 61 84 ± 14
Serum ferritin (ng/ml)
Male 221 300 - 283 182 283 - 342 269 ± 58
Female - - 118 - - - 89 - 104 ± 21
Baseline LAL activity in leukocytes (μmol/g/h) 42↓ 42↓ 33↓ 57↓ 10↓ 42↓ 24↓ 19↓ 34 ± 15
Baseline hepatomegaly (PE) Yes Yes Yes Yes No Yes Yes Yes 88%
Lipid-lowering medications Yes No Yes Yes Yes No Yes Yes 75%
Statin Yes No Yes* Yes No No Yes Yes 63%
Ezetimbe No No Yes* No Yes No No No 25%
Other (niacin, cholestyramine) Yes No No No Yes No No No 25%
Liver volume (MN) 1.36 1.15 0.87 1.30 1.02 1.01 0.98 0.99 1.09 ± 0.17
Hepatic PDFF (%)** n.a. 12.29 10.41 6.00 8.03 4.00 11.05 9.00 8.68 ± 2.92
Subject numbers were allocated at enrolment to LAL-CL01. Subject #4 did not progress to study LAL-CL04 and therefore was not included in this table. Baseline is deﬁned as
date of ﬁrst dose. All demographic and baseline data were assessed prior to ﬁrst infusion in study LAL-CL01, with the exception of liver volume and hepatic PDFF, which
were assessed prior to the ﬁrst infusion in LAL-CL04.
BMI, body mass index; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma glutamyl transpeptidase; LDL, low-density
lipoprotein; HDL, high-density lipoprotein; MN, multiples of normal, where ‘‘normal’’ liver volume in liters is deﬁned as 2.5% of body weight in kg; PDFF, proton density fat
fraction; PE, physical examination.
"Above central lab upper limit of normal.
;Below central lab lower limit of normal.
⁄Subject discontinued medications in between study LAL-CL01 and LAL-CL04.
⁄⁄Four subjects had baseline hepatic PDFF assessed by MRI (multi-echo gradient-echo sequence imaging), two by MRS.
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Fig. 2. Mean hepatic transaminases (U/L) in LAL-CL04 study (n = 8). All one-
week-post-infusion laboratory data are presented one week after the week 24
visit. ALT, alanine transaminase; AST, aspartate aminotransferase; qw, once
weekly; qow, once every other week.
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LAL-CL04, and was referred to the trial centre for liver transplant
assessment. The patient was listed for urgent orthotopic liver
transplant and after two months, liver transplant was carried
out successfully; the patient is currently well.
The data presented include seven subjects treated through to
week 52 and one subject (#2) treated through to week 38.
Demographics and baseline disease characteristics
Demographic and baseline characteristics are described in
Table 1. All subjects were Caucasian and 75% were male. The
mean age at ﬁrst dose for the eight subjects who entered LAL-
CL04 was 31 ± 11 years. Six subjects were receiving treatment
with lipid-modifying therapies, including statins, ezetimibe, and
other medications; despite this, only two of the subjects’ lipid
proﬁles were within the central laboratory reference range prior
to entering the study. Subject #3 discontinued lipid-lowering
medication between studies and had a higher baseline LDL in
LAL-CL04 than in LAL-CL01. This subject re-started lipid-lowering
medications at week 39 (see the serum lipids section).Clinical assessments
Serum transaminases
As previously reported, initiation of treatment with sebelipase
alfa produced a rapid decline in ALT and AST (Fig. 2). Six subjects
had abnormal transaminases at baseline, and all normalized upon
treatment. A transient increase in mean AST was noted at week
24/25 due to an isolated increase in AST in a single subject from
42 U/L to 277 U/L. No obvious cause for this transient increase,
including alcohol consumption or medication change, was
identiﬁed, and testing repeated one week later revealed that
the subject’s AST had returned to 44 U/L. The overall improve-
ments in ALT and AST were sustained through the week 38 and
52 time points. At week 52, sebelipase alfa treated-subjects had
a mean concentration of ALT and AST of 34 U/L and 32 U/L,
respectively. Values were within the central laboratory normal
reference ranges and the mean percentage decreases from
LAL-CL01 baseline were 58% and 40%, respectively (p = 0.016;
n = 7). There was no clear evidence of a dose-related effect in
the time-to-onset or in the magnitude of the reduction in AST
and ALT (Table 2). In subject #2 for whom treatment was paused
at week 38, AST and ALT were decreased from LAL-CL01 baseline
at all the visits prior to pausing treatment.Serum lipids
All seven subjects who received treatment with sebelipase alfa
through week 52 showed decreases from their original
LAL-CL01 baseline concentrations of total cholesterol, LDL, and
increases in HDL, while six showed decreases in TGs. On average,
LDL decreased by 73 ± 31 mg/dl (60%, p = 0.016), total cholesterol
by 71 ± 31 mg/dl (39%, p = 0.016) and TGs by 72 ± 66 mg/dl (36%,
p = 0.047). Additionally, an increase in HDL by 9 ± 6 mg/dl (29%,
p = 0.016) was observed (Fig. 3). The beneﬁcial effects of sebeli-
pase alfa on the lipid proﬁle seen in LAL-CL01 up to week 12 were
also evident across week 12 to 52. For LDL and HDL there was evi-
dence of continued improvement over time with additional
improvements in these parameters between weeks 38 and 52.
For TGs, two of the three subjects on the highest dose had notably
large reductions, but these subjects also had the highest baseline
TG levels, and thus dose and baseline TG levels were confounded.1138 Journal of Hepatology 2014The subject with the greatest reduction in TGs was in the lowest
dose group, and had the third greatest baseline TG level.
Marked post-infusion increases in serum lipids similar to
those seen during the ﬁrst four weeks of dosing [17] were not
seen in the one-week post-infusion sample taken after approxi-
mately six months of treatment (Fig. 4).
Lipid-lowering therapy (combination ezetimibe 10 mg/simva-
statin 20 mg po qd) had been discontinued in subject #3 between
completing LAL-CL01 and beginning of LAL-CL04. At week 39, this
subject resumed therapy with simvastatin (20 mg po qd). There
was evidence that the statin or statin/ezetimibe combination
with sebelipase alfa in this subject had an additive effect on the
reduction in LDL concentrations seen with sebelipase alfa.
Other parameters
The mean GGT decreased from baseline to week 52 (58 to
30 U/L); a similar decline in mean alkaline phosphatase was
observed (89 to 68 U/L). One patient with an elevated GGT at
baseline in study LAL-CL01 (203 U/L) had a clinically signiﬁcant
decrease of GGT to 64 U/L at week 12 of LAL-CL04. At week 52,
this patient had a GGT concentration of 93 U/L.
Additionally, mean C-reactive protein and serum ferritin
decreased from 0.26 to 0.20 mg/L and 240 to 121 ng/ml,
respectively from LAL-CL01 baseline to week 52.
MR-measured hepatic PDFF and liver volumes
Imaging performed at weeks 10 or 12, 24, and 52 demonstrated a
mean decrease in liver volume (MN) from the LAL-CL04 baseline
of 10%, 9%, and 12% (n = 8 at weeks 10 and 24, n = 7 at week 52).
Additionally, a mean relative reduction in the hepatic proton
density fat fraction (PDFF) from LAL-CL04 baseline of 42%, 35%,
and 55%, respectively, was observed (n = 7 at weeks 10 and 24,
n = 6 at week 52) (Fig. 5).
Dose effects
Graphical exploration of the individual subject changes in the
end points did not reveal any apparent trends by dose cohort
(Table 2); however, the sample size in each dose group was
small, and thus the ability to detect dose differences was limited.
For the 6 subjects who received their full dosing regimen,
the cumulative dose (across LAL-CL01 and LAL CL04) at
LAL-CL04 week 52 was 26.8 mg/kg, 32 mg/kg, and 96 mg/kg
for subjects initially assigned to 0.35 mg/kg, 1.0 mg/kg, andvol. 61 j 1135–1142
Table 2. Absolute and relative change from LAL-CL01 baseline in laboratory values at week 52 of LAL-CL04.
Subject 1 2* 3 5 6 7 8 9 Mean ± SD
LAL-CL01 dose (mg/kg) 0.35 0.35 0.35 1 1 3 3 3
LAL-CL04 dose (Wk 1 to 4) 
(mg/kg)
0.35 0.35 0.35 1 1 3 3 3
LAL-CL04 dose (Wk 6 to 52) 
(mg/kg)
1 1 1 1 1 3 3 3
Demographics
Baseline age (yr) 41 29 27 45 19 21 19 41 30 ± 11
Wk 52 laboratory assessments (change from baseline)
ALT (U/L) 34 (-26) - 32 (-53) 29 (-41) 50 (-69) 52 (-34) 18 (-39) 26 (-84) -49 ± 21
AST (U/L) 45 (-11) - 36 (-33) 28 (-24) 30 (-39) 30 (-11) 21 (-16) 37 (-28) -23 ± 11
GGT (U/L) 12 (-28) - 8 (-4) 25 (-17) 14 (-12) 43 (-12) 12 (-11) 93 (-110) -28 ± 37
Total cholesterol (mg/dl) 65 (-65) - 137 (-119) 69 (-47) 121 (-57) 131 (-57) 141 (-41) 108 (-112) -71 ± 31
HDL-cholesterol (mg/dl) 33 (5) - 48 (9) 32 (10) 46 (1) 49 (6) 63 (14) 45 (19) 9 ± 6
LDL-cholesterol (mg/dl) 17 (-57) - 79 (-129) 22 (-48) 58 (-60) 62 (-50) 70 (-65) 40 (-103) -73 ± 31
Triglycerides (mg/dl) 58 (-160) - 43 (-63) 63 (-39) 76 (-16) 131 (-135) 102 (22) 166 (-111) -72 ± 66
ALP (U/L) 92 (-1) - 57 (-19) 60 (-26) 83 (-52) 89 (-11) 60 (-16) 38 (-23) -21 ± 16
Serum ferritin (ng/ml) -96 ± 70
Male 92 (-129) - - 158 (-125) 160 (-22) 144 (-139) - 143 (-199)
Female - - 81 (-37) - - - 70 (-19) -
Subject #4 did not progress to study LAL-CL04 and is therefore not included in this table. Baseline is deﬁned as date of ﬁrst dose.
⁄Subject paused treatment at week 38.
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase. GGT, gamma glutamyl transpeptidase; LDL, low-density lipoprotein; HDL, high-
density lipoprotein.
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JOURNAL OF HEPATOLOGY3.0 mg/kg doses, respectively. The potential dose effects were
graphically explored and no apparent trends were observed.
Safety assessment
216 infusions of sebelipase alfa were administered from week 12
to week 52 in LAL-CL04. Subject #2 experienced CTCAE grade 2
(moderate) hyperaemia and chills 30 min into his week 36
infusion and a similar reaction during his week 38 infusion,
despite pre-treatment with diphenhydramine and acetaminophen.
The week 38 infusion-reaction worsened after discontinuation of100
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Fig. 3. Mean percent change from LAL-CL01 baseline for serum lipids in
LAL-CL04 study (n = 8). All one-week-post-infusion laboratory data are presented
one week after the week 24 visit. HDL, high-density lipoprotein-cholesterol; LDL,
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Journal of Hepatology 2014the infusion and administration of intravenous antihistamines.
Although no changes were noted in the subject’s heart rate, blood
pressure and oxygen saturation during this reaction the subject
reported throat tightness and was administered subcutaneous100
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Research Articleepinephrine. The symptoms resolved over the next three hours.
Given the nature of this reaction and the absence of similar events
in other subjects, treatment was paused in this subject to allow
further investigation. Anti-sebelipase (total and IgE) and anti-
egg-white protein antibodies were negative. Skin testing results
were inconclusive in that a positive skin test at the highest concen-
tration of intradermal sebelipase alfa was seen in both this subject
and a concurrently treated study subject who did not experience a
hypersensitivity reaction. After an independent safety committee
review, the subject was successfully re-started on sebelipase alfa
initially at a reduced dose, infusion rate and pre-medication. The
subject is now receiving his previous dose (1 mg/kg) at the stan-
dard infusion rate. The subject has since received 15 infusions
(as of April 24, 2014) with no recurrence of hypersensitivity-like
symptoms.
One or more AEs were reported by all subjects during the trial.
Events reported by three or more subjects included headache,
cold, sore throat, abdominal pain/cramping, nausea, diarrhoea,
and back pain. AEs were mainly mild and unrelated to sebelipase
alfa. No related serious AEs were reported up to week 52. With
the exception of the infusion-related reaction (IRR) event
described above for subject #2, there was no requirement for
pre-medication or modiﬁcation of the infusion rate due to infu-
sion-related side effects. In the seven subjects who received
treatment up to week 52 and the one who received treatment
up to week 38, no anti-drug antibodies were detected.Discussion
LAL D is a rare, under-diagnosed progressive disease with early
mortality and signiﬁcant morbidity mainly due to liver complica-
tions. In the absence of any approved therapies, medical manage-
ment is largely conﬁned to the use of statins and other lipid-
lowering therapies, and liver transplantation for those with
decompensated cirrhosis and liver failure. The failure of statins
to substantially improve liver manifestations in LAL D patients
is clinically important as liver disease progression is clearly doc-
umented and appears relatively common in patients on statins
who have undergone serial liver biopsies [2].
Sebelipase alfa is well-tolerated, with rapid and consistent
decreases in serum transaminases, and improvements in
dyslipidemia after an initial early rise in serum lipids (due to1140 Journal of Hepatology 2014lysosomal lipid mobilization) and continues to be well-tolerated
with a safety proﬁle largely consistent with previous experience
[17]. Most reported AEs were infrequent, mild and unrelated to
study drug. The most notable new ﬁnding was a possible hyper-
sensitivity-like IRR after 36 weeks of treatment in one subject,
but this subject has successfully re-started treatment. Although
the number of subjects is small, the frequency of IRRs appears
low relative to other approved enzyme replacement therapies
[24].
None of the subjects to date in this study have developed
detectable antibody responses, and this is consistent with the
low frequency of infusion reactions in the overall population.
The reasons for the absence of evidence of immunogenicity of
sebelipase alfa in this LAL D adult population are unknown. It is
possible that the presence of at least one copy of the common
mutation (exon 8 splice junction mutation (c.894G>A) may allow
production of small amounts of residual enzyme in these
adult subjects [25] (Supplementary Table 1) and inﬂuence
immunogenicity.
Assessment up to 52 weeks provides further evidence that
sebelipase alfa produces sustained improvements in markers of
liver damage and in the dyslipidemia associated with LAL D.
The long-term liver effects at week 52 were consistent with those
seen at week 12; the statistically signiﬁcant mean decreases from
baseline in ALT (76 U/L at baseline, decreased by 44 U/L [52%])
and AST (56 U/L at baseline, decreased by 20 U/L ([36%]) seen at
week 12, were maintained up to week 52 (ALT decreased by
49 U/L [58%], p = 0.016; AST decreased by 23 U/L [40%],
p = 0.016). Improvements were also seen in other biochemical
markers of liver disease including reductions in GGT and alkaline
phosphatase. The rapid and sustained improvements in the trans-
aminase proﬁle were accompanied by evidence of reductions in
liver lipid content as evidenced by a mean decrease in liver vol-
ume (12% at week 52) and mean reduction in hepatic PDFF
(55% change from LAL-CL04 baseline to week 52). The concor-
dance of effects on these parameters is expected as treatment
with sebelipase alfa directly addresses the root cause of the dis-
ease and is consistent with ﬁndings from studies in a rat model
of LAL D [15]. Given that the lysosomal accumulation of CE
and/or TG appears to be a potent inducer of liver ﬁbrosis with evi-
dence of ﬁbrosis and cirrhosis within months of birth in the most
severely affected patients [12–14], the normalization of transam-
inases and other hepatic disease markers, and reduction in hepa-
tic PDFF seen in this study suggest that sebelipase alfa may have
the potential of reducing the risk of ﬁbrosis and progression to
cirrhosis.
In addition to the improvements in liver biochemical param-
eters with enzyme replacement, all subjects showed improve-
ments in their lipid proﬁle through week 52. These effects on
lipid proﬁle were maintained from week 12 onwards, with evi-
dence of additional time-dependent improvements in LDL and
HDL through to week 52.
Sebelipase alfa produced a marked reduction in the MR-esti-
mated hepatic PDFF, which suggests that this method can be used
to non-invasively quantify the effects of enzyme replacement and
other interventions in LAL D patients. Substantial reductions
were seen within ten weeks of treatment initiation in LAL-CL04
with further improvements through to week 52. Further support
for the effectiveness of sebelipase alfa in mobilization of lyso-
somal lipid is provided by the marked decrease in the magnitude
of the 1-week post-infusion increase in lipids after more thanvol. 61 j 1135–1142
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20 weeks of dosing compared to the effects seen following initi-
ation of treatment in LAL-CL01 and LAL-CL04.
Although descriptions of the macroscopic liver appearance in
LAL D patients typically describe a striking orange colour, base-
line values for hepatic PDFF from study subjects were relatively
low compared to values described in NAFLD patients. It is possi-
ble that the reported baseline hepatic PDFF measurements in
LAL-CL04 are confounded by the prior administration of four
doses of sebelipase alfa in these subjects from LAL-CL01. While
this possibility cannot be excluded, relatively low hepatic fat frac-
tion values using conventional methodologies developed for
assessing fat content in NAFLD patients, similar to the ones used
in this study, have also recently been reported in LAL D patients
who have not received prior enzyme replacement [26]. Interest-
ingly, in the Thelwall et al. study [26], LAL D rats and LAL D
patients were associated with distinct 1H- and 13C-MRS signa-
tures arising from cholesterol moieties. The high liver cholesterol
content relative to TG compared to NAFLD/NASH patients is con-
sistent with previous biochemical analyses [4,27–29]. These ﬁnd-
ings suggest that fatty liver criteria from radiological methods
developed for quantifying hepatic fat in NAFLD may not be opti-
mal for liver diseases where the lipid composition and/or subcel-
lular localization is distinct from NAFLD.
In summary, this long-term follow-up studyhas shown that the
previously reported beneﬁts of enzyme replacement with sebeli-
pase alfa up to 12 weeks of therapy are sustained through week
52 with signiﬁcant improvements in transaminases, lipid proﬁle,
liver volumes and hepatic PDFF in these LAL D patients. Sebelipase
alfa appears well-tolerated with a low frequency of IRRs and no
evidence of anti-drug antibody formation in this study. In contrast
to many therapies used in the treatment of more common but less
well molecularly deﬁned diseases, sebelipase alfa addresses the
root cause of LAL D with favourable effects on a broad range of
abnormalities described in the affected patients.
Though key limitations of this study include the small number
of patients evaluated and the open-label trial design, these
results are encouraging and additional data from the randomized
placebo-controlled trial (ARISE: NCT01757184) will elucidate the
efﬁcacy and safety of sebelipase alfa in LAL D.Financial support
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